Small node-negative (T1b-cN0) invasive hormone receptor-positive breast cancers: Is there a subpopulation that might have benefit from adjuvant chemotherapy?

Yeon Hee Park, Seock-Ah Im, Eun Yoon Cho, Yoon La Choi, Jeong Eon Lee, Seok Jin Nam, Jung Hyun Yang, Jin Seok Ahn, Young Hyuck Im

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The aims of the study were to identify a subpopulation more likely to be at greater risk of recurrence in small T1b-c node-negative hormone receptor (HR)-positive breast cancer, and which would benefit from adjuvant chemotherapy. Clinico-pathologic characteristics and clinical outcomes of 538 postoperative HR-positive T1b-cN0 breast cancer patients were retrospectively analyzed. High Ki67 index and a young age (<35 years) were identified as independent risk factors for relapse (p < 0.0001 and 0.015, respectively). A nomogram based on Cox-regression model showed an area under the curve (AUC) of 0.73 in the training set. The validation set showed a good discrimination with an AUC of 0.65. In patients with high nomogram scores (100, n = 24, 4.5%) who had high Ki67 index with more than 75%, or young age (<35 years) and a Ki67 index >50%, the relapse-free survival curve of patients who had received anthracycline-containing adjuvant chemotherapy showed a better outcome than those who had not (p = 0.029). Ki67 index and age are valuable surrogate markers to predict recurrence and as indicators of tumors that could benefit from adjuvant chemotherapy in small T1b-c node-negative HR-positive breast cancer.

Original languageEnglish
Pages (from-to)247-255
Number of pages9
JournalBreast Cancer Research and Treatment
Volume133
Issue number1
DOIs
StatePublished - 1 May 2012

Fingerprint

Adjuvant Chemotherapy
Hormones
Breast Neoplasms
Recurrence
Anthracyclines
Biomarkers
Survival
Neoplasms

Keywords

  • 1 cm invasive breast cancer
  • Adjuvant treatment
  • Hormone receptor-positive breast cancer

Cite this

Park, Yeon Hee ; Im, Seock-Ah ; Cho, Eun Yoon ; Choi, Yoon La ; Lee, Jeong Eon ; Nam, Seok Jin ; Yang, Jung Hyun ; Ahn, Jin Seok ; Im, Young Hyuck. / Small node-negative (T1b-cN0) invasive hormone receptor-positive breast cancers : Is there a subpopulation that might have benefit from adjuvant chemotherapy?. In: Breast Cancer Research and Treatment. 2012 ; Vol. 133, No. 1. pp. 247-255.
@article{04c5add1774c4197a4e7bb85a9c7aaf4,
title = "Small node-negative (T1b-cN0) invasive hormone receptor-positive breast cancers: Is there a subpopulation that might have benefit from adjuvant chemotherapy?",
abstract = "The aims of the study were to identify a subpopulation more likely to be at greater risk of recurrence in small T1b-c node-negative hormone receptor (HR)-positive breast cancer, and which would benefit from adjuvant chemotherapy. Clinico-pathologic characteristics and clinical outcomes of 538 postoperative HR-positive T1b-cN0 breast cancer patients were retrospectively analyzed. High Ki67 index and a young age (<35 years) were identified as independent risk factors for relapse (p < 0.0001 and 0.015, respectively). A nomogram based on Cox-regression model showed an area under the curve (AUC) of 0.73 in the training set. The validation set showed a good discrimination with an AUC of 0.65. In patients with high nomogram scores (100, n = 24, 4.5{\%}) who had high Ki67 index with more than 75{\%}, or young age (<35 years) and a Ki67 index >50{\%}, the relapse-free survival curve of patients who had received anthracycline-containing adjuvant chemotherapy showed a better outcome than those who had not (p = 0.029). Ki67 index and age are valuable surrogate markers to predict recurrence and as indicators of tumors that could benefit from adjuvant chemotherapy in small T1b-c node-negative HR-positive breast cancer.",
keywords = "1 cm invasive breast cancer, Adjuvant treatment, Hormone receptor-positive breast cancer",
author = "Park, {Yeon Hee} and Seock-Ah Im and Cho, {Eun Yoon} and Choi, {Yoon La} and Lee, {Jeong Eon} and Nam, {Seok Jin} and Yang, {Jung Hyun} and Ahn, {Jin Seok} and Im, {Young Hyuck}",
year = "2012",
month = "5",
day = "1",
doi = "10.1007/s10549-012-1956-1",
language = "English",
volume = "133",
pages = "247--255",
journal = "Breast cancer research and treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "1",

}

Small node-negative (T1b-cN0) invasive hormone receptor-positive breast cancers : Is there a subpopulation that might have benefit from adjuvant chemotherapy? / Park, Yeon Hee; Im, Seock-Ah; Cho, Eun Yoon; Choi, Yoon La; Lee, Jeong Eon; Nam, Seok Jin; Yang, Jung Hyun; Ahn, Jin Seok; Im, Young Hyuck.

In: Breast Cancer Research and Treatment, Vol. 133, No. 1, 01.05.2012, p. 247-255.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Small node-negative (T1b-cN0) invasive hormone receptor-positive breast cancers

T2 - Is there a subpopulation that might have benefit from adjuvant chemotherapy?

AU - Park, Yeon Hee

AU - Im, Seock-Ah

AU - Cho, Eun Yoon

AU - Choi, Yoon La

AU - Lee, Jeong Eon

AU - Nam, Seok Jin

AU - Yang, Jung Hyun

AU - Ahn, Jin Seok

AU - Im, Young Hyuck

PY - 2012/5/1

Y1 - 2012/5/1

N2 - The aims of the study were to identify a subpopulation more likely to be at greater risk of recurrence in small T1b-c node-negative hormone receptor (HR)-positive breast cancer, and which would benefit from adjuvant chemotherapy. Clinico-pathologic characteristics and clinical outcomes of 538 postoperative HR-positive T1b-cN0 breast cancer patients were retrospectively analyzed. High Ki67 index and a young age (<35 years) were identified as independent risk factors for relapse (p < 0.0001 and 0.015, respectively). A nomogram based on Cox-regression model showed an area under the curve (AUC) of 0.73 in the training set. The validation set showed a good discrimination with an AUC of 0.65. In patients with high nomogram scores (100, n = 24, 4.5%) who had high Ki67 index with more than 75%, or young age (<35 years) and a Ki67 index >50%, the relapse-free survival curve of patients who had received anthracycline-containing adjuvant chemotherapy showed a better outcome than those who had not (p = 0.029). Ki67 index and age are valuable surrogate markers to predict recurrence and as indicators of tumors that could benefit from adjuvant chemotherapy in small T1b-c node-negative HR-positive breast cancer.

AB - The aims of the study were to identify a subpopulation more likely to be at greater risk of recurrence in small T1b-c node-negative hormone receptor (HR)-positive breast cancer, and which would benefit from adjuvant chemotherapy. Clinico-pathologic characteristics and clinical outcomes of 538 postoperative HR-positive T1b-cN0 breast cancer patients were retrospectively analyzed. High Ki67 index and a young age (<35 years) were identified as independent risk factors for relapse (p < 0.0001 and 0.015, respectively). A nomogram based on Cox-regression model showed an area under the curve (AUC) of 0.73 in the training set. The validation set showed a good discrimination with an AUC of 0.65. In patients with high nomogram scores (100, n = 24, 4.5%) who had high Ki67 index with more than 75%, or young age (<35 years) and a Ki67 index >50%, the relapse-free survival curve of patients who had received anthracycline-containing adjuvant chemotherapy showed a better outcome than those who had not (p = 0.029). Ki67 index and age are valuable surrogate markers to predict recurrence and as indicators of tumors that could benefit from adjuvant chemotherapy in small T1b-c node-negative HR-positive breast cancer.

KW - 1 cm invasive breast cancer

KW - Adjuvant treatment

KW - Hormone receptor-positive breast cancer

UR - http://www.scopus.com/inward/record.url?scp=84860332052&partnerID=8YFLogxK

U2 - 10.1007/s10549-012-1956-1

DO - 10.1007/s10549-012-1956-1

M3 - Article

C2 - 22270935

AN - SCOPUS:84860332052

VL - 133

SP - 247

EP - 255

JO - Breast cancer research and treatment

JF - Breast cancer research and treatment

SN - 0167-6806

IS - 1

ER -